Navigation Links
Precision Therapeutics' ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer
Date:4/12/2011

PITTSBURGH, April 12, 2011 /PRNewswire/ -- Drs. Rodney Landreneau and Matthew Schuchert from the University of Pittsburgh presented a new non small cell lung cancer study at the 2011 Society of Surgical Oncology (SSO) conference in San Antonio, Texas.  Dr. Landreneau is Director of the Lung Center at UPMC Shady Side Hospital as well as the Head of Thoracic Surgery at UPMC Passavant Medical Center and Director of the Division of Cardiothoracic Surgery at UPMC St. Margaret Medical Center.  Dr. Matthew J. Schuchert is an Assistant Professor of Surgery in the Department of Cardiothoracic Surgery at the University of Pittsburgh Cancer Institute.  

The study, titled,  "Assessment of In Vitro Chemoresponsiveness to Platinum Based Chemotherapy Doublets Lead to Improvements in 'Individualized' Therapy for Resected Non Small Cell Lung Cancer (NSCLC),"  demonstrates that while 35% of patient specimens evaluated in vitro are resistant to all three standard platinum doublets tested, 28% demonstrate a uniquely variable response, suggesting therefore that ChemoFx® chemoresponse testing may help guide optimal selection of the platinum doublet for treatment, a factor that may be crucial to the patient's outcome.

Christine Gan, Ph.D., a medical science liaison for Precision Therapeutics, noted, "Selecting the optimal platinum doublet for individual NSCLC patients is not straightforward when three equally efficacious options exist.  ChemoFx®, when used as a tool in conjunction with a physician's clinical judgment, can potentially help guide the selection of therapy in this difficult to treat disease."

According to recent statistics, lung cancer is currently responsible for 29% of cancer deaths in the United States, which represents more deaths than breast cancer, colon cancer, and prostate cancer combined. Lung cancer remains the leading cause of cancer deaths for both men and women.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients.  As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.  

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

ChemoFx® is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.  Precision currently receives ChemoFx® specimens from 271 top medical institutions including 20 of the 21 National Comprehensive Cancer Network (NCCN) Member Institutions, and 8 of the US News and World Report Top 10 Hospitals for Cancer Care. To date, ChemoFx® Final Reports have been provided for over 56,000 patient specimens, using 105 unique chemotherapy treatments and combinations. For more information, visit www.precisiontherapeutics.com or www.chemofx.com


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
2. Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes
3. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
4. AMDL, Inc. Signs First Customer Agreement With Precision Diagnostic Laboratory for DR-70 (FDP) Cancer Test
5. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
6. NISTs LIDAR may offer peerless precision in remote measurements
7. Precision Stability Storage Announces Upcoming Expansion
8. New statistical technique improves precision of nanotechnology data
9. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
10. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
11. Stretching single molecules allows precision studies of interacting electrons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... At its ... Dr. Christopher Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has ... was a member of the winning team for the 2015 Breakthrough Prize in Fundamental ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses ... EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first ... accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own ...
Breaking Biology Technology:
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):